OpenAIスタッフが退職、安全性を後にして20億ドルの創薬へ
OpenAIの研究者Miles Wangが、20億ドル規模のAI創薬スタートアップのために2億ドルを調達するため退職しました。この人材流出は、汎用モデルから専門性の高い高価値なバイオテック応用への大規模なベンチャーキャピタルのシフトを浮き彫りにしています。
openai researcher miles wang is in talks to raise $200 million at a $2 billion valuation for a new ai drug discovery startup, with lightspeed venture partners leading the round. wang, who joined openai in 2024 after dropping out of harvard, aims to develop models that identify new uses for existing drugs to shorten the time to revenue. this exit coincides with a booming market for generative biology, chai discovery recently raised $400m at a $3.8b valuation, and isomorphic labs secured $2.1b in may. the flurry of funding indicates that while general llm development faces high costs and monetization hurdles, investors are betting heavily on ai's ability to solve expensive bottlenecks in life sciences.